PYRROLOPYRIDAZINONE COMPOUND
    14.
    发明专利

    公开(公告)号:CA2637388A1

    公开(公告)日:2007-07-19

    申请号:CA2637388

    申请日:2007-01-16

    Applicant: UBE INDUSTRIES

    Abstract: The present invention discloses a pyrrolopyridazinone compound represented by the formula (1): wherein R 1 represents C 1 -C 2 alkyl group or halogeno C 1 -C 2 alkyl group, R 2 repersents C 3 -C 5 cycloalkyl group, (C 3 -C 5 cycloalkyl)C 1 -C 2 alkyl group or C 1 -C 3 alkyl group, R 3 represents hydrogen atom, or methylene group or cis-vinylene group for forming substituted oxygen-containing hetero ring in combination with group -O-R 2 , R 4 represents hydrogen atom, halogen atom, C 1 -C 8 alkyl group, C 2 -C 6 alkenyl group, C 2 -C 6 alkynyl group, hydroxy C 3 -C 6 alkenyl group, hydroxy C 3 -C 6 alkynyl group, C 1 -C 6 alkyl group substituted by substituent(s) selected from Substituent group (a), C 3 -C 6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), "C 1 -C 3 alkyl group which is substituted by C 3 -C 6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), and which may be substituted by a hydroxy group", an aromatic ring group or heteroaromatic ring group each of which may be substituted by a substituent(s) selected from Substituent group (c) or "C 1 -C 2 alkyl group which is substituted by aromatic ring group or heteroaromatic ring group each of which may be substituted by group(s) selected from Substituent group (c), and which may be substituted by a hydroxy group", Substituent group (a) represents a halogen atom, hydroxy group, cyano group, carboxy group, C 1 -C 5 alkoxy group, halogeno C 1 -C 4 alkoxy group, C 3 -C 6 cycloalkoxy group, (C 3 -C 6 cycloalkyl) C 1 -C 2 alkoxy group, C 1 -C 4 alkoxycarbonyl group, C 2 -C 4 alkanoyl group, C 2 -C 4 alkanoyloxy group or C 1 -C 4 alkyl-substituted amino group, Substituent group (b) represents a hydroxy group or a halogen atom, Substituent group (c) represents a halogen atom, a hydroxy group, a cyano group, a nitro group, a carboxy group, C 1 -C 5 alkoxy group, C 1 -C 4 alkoxycarbonyl group, C 2 -C 4 alkanoyloxy group, C 1 -C 4 alkyl-substituted amino group or a C 1 -C 4 alkyl group which may be substituted by a substituent(s) selected from the group consisting of (a halogen atom, a hydroxy group and a carboxy group), or a pharmaceutically acceptable salt thereof.

    15.
    发明专利
    未知

    公开(公告)号:CZ20033519A3

    公开(公告)日:2004-06-16

    申请号:CZ20033519

    申请日:2002-06-27

    Applicant: UBE INDUSTRIES

    Abstract: Dibenzocycloheptene derivatives (I) are new. Dibenzocycloheptene derivatives of formula (I) and their salts are new. [Image] R1H, halo, OH, NO2, CN, CONH2, CHO, COOH, 1H-tetrazol-5-yl, Alk1, 1-4C hydroxyalkyl, 2-4C alkenyl, 2-4C alkynyl, S(O)bAlk or OAlk1; Alk : 1-4C alkyl; Alk1Alk or 1-4C fluoroalkoxy; R2H, halo, NO2, CN, Alk or OAlk; A : 5- or 6-membered optionally benzofused aromatic heterocyclyl containing 1-3 O, S or N and optionally substituted by halo, NO2, CN, Alk1, OAlk1, SAlk or 3 or 4C alkylene; B : CH=CH, CH2O, CH2CH2, CH2S, OCH2 or SCH2; X : O, S, CH2 or =CH; Y : 1-10C alkylene (optionally substituted by halo, Alk or OAlk) or a group of formula (i); b, o, p : 0-2; Z : optionally protected carboxyl, 1H-tetrazol-5-yl, NHSO2R3 or CONHSO2R3; R3Alk1 or phenyl (optionally substituted by halo, Alk1, OAlk1, NO2 or CN); m : 1-4, and n : 1-3. [Image] ACTIVITY : Antiasthmatic; Antiallergic; Antiinflammatory. In tests on guinea pigs, [3-[(E)-2-(6,7-difluoroquinolin-2-yl)ethenyl]-5H-dibenzo[a,d]cyclohepten-5-yl]oxyacetic acid (Ia) in an amount of 0.70 mu g/kg orally inhibited leukotriene D4 induced bronchoconstriction. MECHANISM OF ACTION : Leukotriene-D4 antagonist; Leukotriene-C4 antagonist; Leukotriene-E4 antagonist.

    DIBENZOCYCLOHEPTENE COMPOUND
    16.
    发明专利

    公开(公告)号:CA2452105A1

    公开(公告)日:2003-01-09

    申请号:CA2452105

    申请日:2002-06-27

    Applicant: UBE INDUSTRIES

    Abstract: A dibenzocycloheptene compound represented by the general formula (I): (I) (wherein R1 represents hydrogen, halogeno, etc.; R2 represents hydrogen, halogeno, etc.; A represents, e.g., a 5- or 6-membered heterocyclic aromatic group containing one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, the heterocyclic aromatic group optionally having halogeno, nitro, etc. as a substituent; B represents -CH=CH-, -CH2O-, etc.; Y represents C1-10 alkylene optionally having halogeno, etc. as a substituent; Z represents optionally protected carboxyl, etc.; m is an integ er of 1 to 4; n is an integer of 1 to 3; and ~~ indicates a single bond or doub le bond) or a pharmacologically acceptable salt of the compound; and a medicina l composition which contains the compound or salt as the active ingredient. Th e composition has not only strong leucotriene D4 antagonism but leucotriene C4 antagonism and leucotriene E4 antagonism. It is useful as an antasthmatic, antiallergic, or antiphlogistic.

    Compuesto de pirrolopiridazinona como inhibidor de PDE4

    公开(公告)号:ES2383969T3

    公开(公告)日:2012-06-27

    申请号:ES07706860

    申请日:2007-01-16

    Applicant: UBE INDUSTRIES

    Abstract: Un compuesto de pirrolopiridazinona representado por la fórmula (1):en la queR2 representa un grupo alquilo C1-C2 o un grupo halo-alquilo C1-C2,R2 representa un grupo cicloalquilo C3-C5, un grupo (cicloalquilo C3-C5)-alquilo C1-C2 o un grupo alquilo C1-C3,R3 representa un átomo de hidrógeno, o un grupo metileno o un grupo cis-vinileno, cada uno de los cuales es un grupopara la constitución de un anillo heterocíclico que contiene oxígeno sustituido junto con un grupo -O-R2,R4 representa un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C1-C8, un grupo alquenilo C2-C6, ungrupo alquinilo C2-C6, un grupo hidroxi-alquenilo C3-C6, un grupo hidroxi-alquinilo C3-C6, un grupo alquilo C1-C6sustituido con un sustituyente o sustituyentes seleccionados entre el Grupo de sustituyentes (a), un grupo cicloalquiloC1-C6, que puede estar sustituido con un sustituyente o sustituyentes seleccionados entre el Grupo de Sustituyentes(b), "un grupo alquilo C1-C3 que está sustituido con un grupo cicloalquilo C3-C6, que puede estar sustituido con unsustituyente o sustituyentes seleccionados entre el Grupo de Sustituyentes (b), y que puede estar sustituido con ungrupo hidroxi", un grupo de anillo aromático o un grupo de anillo heteroaromático, pudiendo estar cada uno de loscuales sustituido con un sustituyente o sustituyentes seleccionados entre el Grupo de Sustituyentes (c), o "un grupoalquilo C1-C2 que está sustituido con un grupo de anillo aromático o un grupo de anillo heteroaromático, estando cadauno de los cuales sustituido con un sustituyente o sustituyentes seleccionados entre el Grupo de Sustituyentes (c), yque puede estar sustituido con un grupo hidroxi",El Grupo de sustituyentes (a) representa un átomo de halógeno, un grupo hidroxi , un grupo ciano, un grupo carboxi, ungrupo alcoxi C1-C5, un grupo halo-alcoxi C1-C4, un grupo cicloalcoxi C3-C6, un grupo (cicloalquil C3-C6)alcoxi C1-C2, ungrupo alcoxicarbonilo C1-C4, un grupo alcanoílo C2-C4, un grupo alcanoiloxi C2-C4 o un grupo amino sustituido conalquilo C1-C4, el Grupo de Sustituyentes (b) representa un grupo hidroxi o un átomo de halógeno,el Grupo de Sustituyentes (c) representa un átomo de halógeno, un grupo hidroxi, un grupo ciano, un grupo nitro, ungrupo carboxi, un grupo alcoxi C1-C5, un grupo alcoxicarbonilo C1-C4, un grupo alcanoiloxi C2-C4, un grupo aminosustituido con alquilo C1-C4 o un grupo alquilo C1-C4, que puede estar sustituido con un sustituyente o sustituyentesseleccionados entre el grupo que consiste en (un átomo de halógeno, un grupo hidroxi y un grupo carboxi), o una salfarmacéuticamente aceptable de los cuales.

Patent Agency Ranking